alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–24 of 24 studies by Pankratz VS · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Other authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Archives of general psychiatry 2008-10-01

Multivariate logistic regression analyses were conducted after adjusting for age, sex, and educational status. 1 key finding →

Design: cohort study Participants: 1,969 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Genome-wide association study of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Translational psychiatry 2012-05-15

In addition to apolipoprotein E (APOE), recent large genome-wide association studies (GWASs) have identified nine other genes/loci (CR1, BIN1, CLU, PICALM, MS4A4/MS4A6E, CD2AP, CD33, EPHA1 and ABCA7) for late-onset Alzheimer's disease (LOAD). 4 key findings →

Design: meta-analysis Evidence: high

Full summary, score breakdown and related studies → Original source

Physical exercise, aging, and mild cognitive impairment: a population-based study

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Archives of neurology 2010-01-01

In this population-based case-control study, any frequency of moderate exercise performed in midlife or late life was associated with a reduced odds of having MCI. 5 key findings →

Design: cohort study Participants: 1,324 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Diabetes and elevated hemoglobin A1c levels are associated with brain hypometabolism but not amyloid accumulation

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2014-03-20

These factors should be investigated in longitudinal studies for their role in detecting onset of symptoms in AD. 1 key finding →

Design: longitudinal study Participants: 749 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Neurology 2010-09-01

Among 1,969 subjects without dementia, 329 subjects had MCI, with a prevalence of 16.0% (95% confidence interval [CI] 14.4-17.5) for any MCI, 11.1% (95% CI 9.8-12.3) for amnestic MCI, and 4.9% (95% CI 4.0-5.8) for nonamnestic MCI. 3 key findings →

Participants: 1,969 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Neurology 2013-12-18

Over a median follow-up of 5.1 years, 153 of 534 participants (28.7%) with prevalent or incident MCI progressed to dementia (71.3 per 1,000 person-years). 2 key findings →

Participants: 534 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Mild cognitive impairment due to Alzheimer disease in the community

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Annals of neurology 2013-08-01

The NIA-AA criteria apply to most MCI subjects in both the community and clinical trials settings; however, a sizeable proportion of subjects had conflicting biomarkers, which may be very important and need to be explored. 2 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: a population-based study

✓ Peer-reviewed alzhub usefulness score 60 out of 100. The American journal of psychiatry 2014-05-01

An increased incidence of mild cognitive impairment was observed in community-dwelling elderly adults who had nonpsychotic psychiatric symptoms at baseline. 3 key findings →

Design: cohort study Participants: 365 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Risk factors for dementia with Lewy bodies: a case-control study

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Neurology 2013-07-26

Smoking and education, which have opposing risk effects on AD and PD, are not risk factors for DLB; however, depression and low caffeine intake, both risk factors for AD and PD, increase risk of DLB more strongly than in either. 2 key findings →

Participants: 147 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Neuroepidemiology 2008-02-07

Strengths of the study are that the subjects were randomly selected from a defined population, the majority of the subjects were examined in person, and MCI was defined using published criteria. 1 key finding →

Participants: 2,719 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Glutathione S-transferase omega genes in Alzheimer and Parkinson disease risk, age-at-diagnosis and brain gene expression: an association study with mechanistic implications

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Molecular neurodegeneration 2012-04-11

These results suggest that GSTO locus variants may lower brain GSTO2 levels and consequently confer AD risk in older age. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Validation of the telephone interview for cognitive status-modified in subjects with normal cognition, mild cognitive impairment, or dementia

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neuroepidemiology 2009-11-05

The extensive in-person assessment classified 83 persons with normal cognition, 42 persons with MCI, and 42 persons with dementia. 1 key finding →

Participants: 83 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Spectrum of cognition short of dementia: Framingham Heart Study and Mayo Clinic Study of Aging

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Neurology 2015-10-09

We quantitated risk of progression to dementia in elderly persons without dementia from 2 population-based studies, the Framingham Heart Study (FHS) and Mayo Clinic Study of Aging (MCSA), aged 70 to 89 years at enrollment. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Late-onset Alzheimer's risk variants in memory decline, incident mild cognitive impairment, and Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Neurobiology of aging 2014-08-04

We tested association of nine late-onset Alzheimer's disease (LOAD) risk variants from genome-wide association studies (GWAS) with memory and progression to mild cognitive impairment (MCI) or LOAD (MCI/LOAD) in older Caucasians, cognitively normal at baseline and longitudinally evaluated at Mayo Clinic Rochester and Jacksonville (n>2000). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Nature genetics 2009-01-11

By analyzing late-onset Alzheimer's disease (LOAD) in a genome-wide association study (313,504 SNPs, three series, 844 cases and 1,255 controls) and evaluating the 25 SNPs with the most significant allelic association in four additional series (1,547 cases and 1,209 controls), we identified a SNP (rs5984894) on Xq21.3 in PCDH11X that is strongly associated with LOAD in individuals of European descent from the United States. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed